Biodesix announces preliminary revenue for third quarter 2022

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 2021. the strength in the third quarter 2022 total revenue reflects continued growth in the company's core lung diagnostic testing. the financial results inclu
BDSX Ratings Summary
BDSX Quant Ranking